Shopping Cart
Remove All
Your shopping cart is currently empty
VEGFR2/KDR Protein, Human, Recombinant (aa 20-764, His & Avi), Biotinylated
(Synonyms: VEGFR-2, Vascular endothelial growth factor receptor 2, Protein-tyrosine kinase receptor flk-1, Kinase insert domain receptor, KDR, FLK-1, Fetal liver kinase 1) Copy Product InfoSynonyms: VEGFR-2, Vascular endothelial growth factor receptor 2, Protein-tyrosine kinase receptor flk-1, Kinase insert domain receptor, KDR, FLK-1, Fetal liver kinase 1
Catalog No. TMPJ-00414 Copy Product Info
VEGFR2/KDR Protein, Human, Recombinant (aa 20-764, His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-6xHis-Avi tag. The predicted molecular weight is 120-150 KDa and the accession number is P35968.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 5 μg | $129 | 35 days | 35 days | |
| 10 μg | $213 | 35 days | 35 days | |
| 20 μg | $355 | 35 days | 35 days | |
| 50 μg | $625 | 35 days | 35 days | |
| 100 μg | $963 | 35 days | 35 days |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Bioactivity | 1. Loaded Anti-Human VEGFR2 mAb-Fc on Protein A Biosensor, can bind Biotinylated Human VEGFR2-6His-Avi with an affinity constant of 1.1 pM as determined in BLI assay. (Regularly tested)
2. Immobilized Biotinylated Human VEGFR2-His-Avi at 1μg/ml (100 μl/well)can bind Anti-Human VEGFR2 mAb. The ED50 of Anti-Human VEGFR2 mAb is 44.08 ng/ml. (Regularly tested) |
| Description | VEGFR2/KDR Protein, Human, Recombinant (aa 20-764, His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-6xHis-Avi tag. The predicted molecular weight is 120-150 KDa and the accession number is P35968. |
| Species | Human |
| Expression System | HEK293 Cells |
| Tag | C-6xHis-Avi |
| Accession Number | P35968 |
| Amino Acid | Ala20-Glu764 |
| Construction | Ala20-Glu764 |
| Protein Purity | Greater than 95% as determined by reducing SDS-PAGE. (QC verified) |
| Endotoxin | < 0.1 ng/µg (1 EU/µg) as determined by LAL test. |
| Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. |
| Reconstitution | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
| Stability & Storage | Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| Shipping | In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice. |
| Synonyms | VEGFR-2, Vascular endothelial growth factor receptor 2, Protein-tyrosine kinase receptor flk-1, Kinase insert domain receptor, KDR, FLK-1, Fetal liver kinase 1 |
| Research Background | Human Vascular endothelial growth factor receptor 2(KDR, VEGFR-2) is a member of the class III subfamily of receptor tyrosine kinases (RTKs). KDR is involved in a number of fundamental biological processes such as the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. It also plays an essential role in promoting proliferation, survival, migration and differentiation of endothelial cells, reorganization of the actin cytoskeleton. VEGFR2 is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo.The adaptor protein SHB has been shown to interact with VEGFR2 in receptor tyrosine kinase signaling. In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis. |
| Molecular Weight | 120-150 KDa (reducing condition) |
| Storage | Lyophilized powder: -20~-80°C for 1 year | Solution: -80°C for 6 months |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: VEGFR2/KDR Protein, Human, Recombinant (aa 20-764, His & Avi), Biotinylated chemical structure | VEGFR2/KDR Protein, Human, Recombinant (aa 20-764, His & Avi), Biotinylated molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.